The startup develops precision therapeutics targeting inflammatory, neurological, chronic, and metabolic diseases by utilizing the gut microbiome's role in these conditions to create novel small molecule therapeutics. This approach enables pharmaceutical companies to efficiently hypothesize and develop targeted treatments, enhancing the drug development process.
Funding
Funding not disclosed
Founders
Product
Problem
Current drug development for inflammatory, neurological, chronic, and metabolic diseases often overlooks the gut microbiome's significant role, leading to less effective and potentially harmful treatments. Traditional methods lack the precision to target specific microbial mechanisms involved in disease progression. This results in therapies with broad effects, increasing the risk of side effects and limiting efficacy.
Solution
Piton Therapeutics is developing precision therapeutics by targeting the gut microbiome's causal role in chronic and systemic diseases. The company's approach involves creating disease-specific, multidimensional, ecological models of the gut microbiome to identify causal factors. Piton's proprietary, AI-enabled drug discovery engine facilitates efficient selection of lead molecules, focusing on both large and small molecule drugs to accurately target mechanisms of action in the gut microbiome. Their orally dosed, gut-restricted therapeutics are designed to have minimal side effects, offering a more targeted and effective treatment option. The company is currently conducting Investigational New Drug (IND)-enabling studies for precision, small molecule drugs targeted at treating Ulcerative Colitis and Type 2 Diabetes, with ongoing research into Autism Spectrum Disorder and Parkinson's Disease.
Target Audience
Piton Therapeutics primarily targets pharmaceutical companies seeking to enhance their drug development process with precision therapeutics, as well as patients suffering from neurological, metabolic, and inflammatory diseases.
Features
- Disease-specific, multidimensional, ecological models of the gut microbiome
- AI-enabled drug discovery engine for efficient lead molecule selection
- Orally dosed, gut-restricted therapeutics for targeted action
- Focus on both large and small molecule drugs
- Investigational New Drug (IND)-enabling studies for Ulcerative Colitis and Type 2 Diabetes
- Research programs for Autism Spectrum Disorder and Parkinson's Disease